Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Using Artificial Intelligence to Phenotype Generalized Pustular Psoriasis: Getting the Right Patients, The Right Treatment, at the Right Time
Description
In a session led by Marta Van Beek from the University of Iowa, the focus is on the use of artificial intelligence (AI) in phenotyping generalized pustular psoriasis (GPP) to enhance patient treatment. The discussion begins with an overview of Dataderm, a clinical data registry launched by the Academy in 2016, which integrates data from various electronic health records (EHR) to assist dermatologists in documenting patient journeys without needing double data entry. Dataderm has compiled data from over 14 million unique patients, allowing for comprehensive insights into treatment patterns, medication access, and quality measures within the specialty of dermatology. A significant aspect of the discussion highlights the importance of natural language processing in extracting valuable information from clinical notes, which is crucial for diagnosing conditions like GPP. AI, referred to as augmented intelligence, is emphasized as a tool to support clinical decisions rather than replace them. The session outlines the necessity for accurate data to ensure effective AI training and addresses the importance of oversight to mitigate bias in clinical applications. The audience can expect insights from subsequent speakers on real-world applications of AI in dermatology, particularly its role in identifying the right patients for appropriate treatment strategies.
View moreConclusions
- The study utilizes a substantial clinical data registry, DataDerm, to collect insights on generalized pustular psoriasis (GPP) patient journeys.
- DataDerm has emerged as the world's largest dermatologic clinical data registry, facilitating research and treatment pattern analysis.
- Artificial intelligence (AI) is employed to identify GPP patients and enhance treatment outcomes through pattern recognition in collected data.
- The accuracy of AI models is heavily reliant on the quality and reliability of the data used during training.
- The collaboration between DataDerm and OM1 enhances data extraction and analytical capabilities, improving outcomes for patients.
- Clinical performance reporting through MIPS has shown improvement among DataDerm members over time, indicating better treatment protocols and management of GPP.
- Augmented intelligence is emphasized as a complementary tool to enhance clinician decision-making rather than replace it.
- Future developments in predictive analytics will focus on leveraging machine learning to anticipate patient needs and treatment responses based on historical data.
- American Academy of Dermatology. Position Statement on Augmented Intelligence (AI) (Approved by the Board of Directors: May 18, 2019).